StockVS

Synlogic, Inc. (SYBX) Stock Analysis

Healthcare

Synlogic, Inc.

$0.66

+$0.00 (+0.00%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

Synlogic, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it was previously engaged in the discovery and development of synthetic biotics intended to treat metabolic diseases. The company is currently based in Winchester, Massachusetts, and its business description indicates that it does not have significant ongoing operations at this time. According to the available data, Synlogic, Inc. holds a market capitalization of $7.16M, while its annual revenue is not available for reporting, and the company lists one employee. These valuation figures and operational constraints suggest that the company exists as a small-cap entity with limited financial scale, reflecting a position where it may be in a transitional phase or maintaining a minimal operational footprint rather than executing large-scale commercial activities typical of fully mature biotechnology firms.

Financial Health

The financial profile of Synlogic, Inc. reveals a net income (TTM) of $-1,005,000 and an EBITDA of $-3,185,000, while revenue data is not available for the trailing twelve months. The substantial gap between the reported net income and the significantly larger negative EBITDA implies that the company has incurred non-operating losses or interest expenses that contribute to the net loss beyond its core operational cash burn. Free cash flow stands at $-5,394,500, indicating that the company is consuming cash reserves to fund its activities rather than generating liquidity from operations. This negative cash flow position suggests that the company relies on external capital sources or existing cash balances to sustain its operations and research efforts. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, which indicates that the company is not currently generating positive profitability on its sales or operations. The balance sheet shows a cash position of $14.67M with no debt recorded, as the debt metric is not available, while the debt-to-equity ratio is also not available. Despite the absence of recorded debt, the company maintains a current ratio of 4.30, which signifies strong short-term liquidity and the ability to cover short-term obligations more than four times over with available current assets. Return on Equity is reported at -8.2% and Return on Assets at -12.5%, metrics that reveal management is currently generating negative returns on the capital invested in the company and its asset base, consistent with the losses observed in the income statement.

Valuation Assessment

Valuation multiples for Synlogic, Inc. present a mixed picture given the lack of positive earnings. The trailing P/E ratio is not available, while the forward P/E is listed as -1.30, a negative figure that implies the market expects earnings to remain negative or that valuation models are relying on projected data rather than historical profitability. The price-to-book ratio is 0.60, suggesting that the market values the company at 60% of its book value, which often indicates a depressed valuation or a market that does not assign a significant premium to the company's intangible assets or intellectual property. Alternative valuation metrics include a price-to-sales ratio that is not available and an EV/EBITDA of 2.36, which provides a perspective on valuation relative to enterprise value despite the negative earnings profile. The stock has traded between a 52-week high of $1.96 and a 52-week low of $0.54; without the specific current share price to calculate the exact percentage, the trading range defines the volatility envelope within which the asset has moved over the past year. The beta value is 0.53, indicating that the stock is less volatile than the broader market, as it typically moves with less intensity than the overall market index.

Growth & Income

Growth metrics for Synlogic, Inc. show that revenue growth year-over-year is not available and earnings growth year-over-year is not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Because the company is not a dividend payer, the dividend yield is not available and the payout ratio is 0.0%, which is consistent with a firm that reinvests all available resources or relies on external funding rather than distributing income to shareholders. The absence of a dividend yield and a zero payout ratio confirms that the company prioritizes capital retention for operations or future development over returning cash to investors. Consequently, the overall growth and income profile is defined by the lack of historical growth data and the absence of dividend income, leaving the investment case dependent entirely on potential future operational milestones or asset realization.

Peer Comparison

Synlogic, Inc. (SYBX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Synlogic, Inc. SYBX $7.72M N/A
Vertex Pharmaceuticals Incorporated VRTX $110.64B 25.8
Regeneron Pharmaceuticals, Inc. REGN $66.98B 15.6
argenx SE ARGX $50.52B 36.0

The Biotechnology industry average P/E ratio is 53.8x. Synlogic, Inc. trades at a P/E of N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Synlogic, Inc.

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.

Visit website →

Key Statistics

Market Cap
$7.72M
P/E Ratio
N/A
52-Week High
$1.96
52-Week Low
$0.54
Avg Volume
13.71K

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
PNK
Country
United States
Employees
1